P042 | PU.1 as master regulator of acute myeloid leukemia venetoclax resistance
Introduction. Venetoclax-based therapies have improved outcomes in acute myeloid leukemia (AML), especially in elderly or unfit patients. However, resistance remains a major limitation. Recent studies suggest that monocytic differentiation (FAB M4/M5) is associated with reduced venetoclax sensitivi...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Ferrata Storti Foundation
2026-03-01
|
| Col·lecció: | Haematologica |
| Accés en línia: | https://haematologica.org/article/view/13306 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|